https://www.selleckchem.com/pr....oducts/tat-beclin-1-
Medicare Part B payment methods incentivize the use of more expensive injectable and infused drugs. We examined prescribing patterns in the context of intravenous (IV) iron, for which multiple similarly safe and efficacious formulations exist, with wide variations in price. We conducted a retrospective cohort analysis of IV iron utilization and payment in the Medicare population between 2015 and 2017. This analysis used a national, random 20% sample of Medicare fee-for-service beneficiaries with Part B claims for IV iron
Like
Comment
Share
